強直性脊椎炎でTNF阻害薬効果不十分または二次無効患者における、次のTNF阻害薬またはsecukinumabの臨床的有効性
Mod Rheumatol. 2023 doi: 10.1093/mr/roac005
This study demonstrated comparable drug retention between AS patients treated with alternative TNFi and secukinumab after failing to respond to prior TNFi therapy. The objective of this study was to compare the drug retention times and clinical efficacy of alternative TNFi and secukinumab in primary and secondary
non-responders with AS.
This data will influence decision making in respect to changing biologics in patients who fail prior TNFi therapy. In particular, clinicians can base the decision on whether the AS patient is a primary or secondary non-responder.
Keywords:
